Examining Real-World Adherence to Nusinersen for the Treatment of Spinal Muscular Atrophy Using Two Large US Data Sources

INTRODUCTION: Spinal muscular atrophy (SMA) is a rare neuromuscular disease characterized by progressive muscular atrophy and weakness. Nusinersen was the first treatment approved for SMA. Per the US label, the nusinersen administration schedule consists of three loading doses at 14-day intervals, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Youn, Bora, Proud, Crystal M., Wang, Nasha, Hou, Qiang, Viscidi, Emma, Eaton, Susan, Paradis, Angela D., Neville, Bridget A., Johnson, Nicole B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9841927/
https://www.ncbi.nlm.nih.gov/pubmed/36645543
http://dx.doi.org/10.1007/s12325-022-02414-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9841927/
https://www.ncbi.nlm.nih.gov/pubmed/36645543
http://dx.doi.org/10.1007/s12325-022-02414-9

Ejemplares similares